Long-term persistence and safety of AAV-NGF gene therapy beyond 15 years in human Alzheimer's disease (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR262.14 / V23; Pres time: Nov 17, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "While microglia were present in regions of NGF expression, they were not associated with neuronal loss. Moreover, NGF gene expression remained detectable for at least 15 years after treatment, the longest time point received to date.We conclude that AAV2 supports safe and long-lasting gene expression for at least 15 years in the degenerating human brain."
Clinical • Gene therapy • Alzheimer's Disease • CNS Disorders • Movement Disorders • Muscular Atrophy • NGF
|
|
H. ZIA1; Y. MAGAÑA2; D. BARBA3; B. T. HARRIS4
|